Updated results reinforce the potential of TAR-210 to transform treatment of non-muscle-invasive bladder cancer with fibroblast growth factor receptor.
Study highlights opportunity for treatment intensification in this population since approximately 50 percent of patients with high-risk localised prostate.
Johnson & Johnson announces that it will sponsor eight data presentations at the 2024 annual meeting of the Association for Research in Vision and Ophthalmology , to be held in Seattle from May 5 to.
TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk non-muscle-invasive bladder cancer bubblear.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bubblear.com Daily Mail and Mail on Sunday newspapers.